Abstract
Fifty-six patients affected with hereditary angioedema have been followed during long-term prophylaxis with attenuated androgens. The treatment was started in patients who had one or more severe attacks per month. In 24 patients, the therapy lasted for more than 5 years. The minimal effective dose usually did not exceed 2 mg/day of stanozolol or 200 mg/day of danazol. Only in two patients were these doses not sufficient to achieve the complete disappearance of symptoms. Irregular menstruation, but rarely amenorrhea, was the only significant side effect. One patient had to stop the therapy because of laboratory signs of hepatic cell necrosis. In one patient, danazol was administered during the last 8 weeks of pregnancy without side effects for the mother but with transient signs of virilization for the female baby. To find a biochemical marker for the minimal effective dose of androgen derivatives, we measured the plasma levels of C1 C1 INH complexes at different doses of stanozolol in four patients with hereditary angioedema. We found that these complexes, elevated before treatment, promptly reverted to normal values during androgen therapy and remained normal with any reduction of the dose of the drug as long as the patient remained symptom free. Therefore, the measurement of C1 C1 INH complexes appears to reflect the activity of the disease and not the amount of androgen that is administered. (J Allergy Clin Immunol 1991;87:768-73.).
| Original language | English |
|---|---|
| Pages (from-to) | 768-773 |
| Number of pages | 6 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 87 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Long-term treatment of hereditary angioedema with attenuated androgens : A survey of a 13-year experience. / Cicardi, Marco; Bergamaschini, Luigi; Cugno, Massimo; Hack, Erik; Agostoni, Giovanni; Agostoni, Angelo.
In: Journal of Allergy and Clinical Immunology, Vol. 87, No. 4, 1991, p. 768-773.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term treatment of hereditary angioedema with attenuated androgens
T2 - A survey of a 13-year experience
AU - Cicardi, Marco
AU - Bergamaschini, Luigi
AU - Cugno, Massimo
AU - Hack, Erik
AU - Agostoni, Giovanni
AU - Agostoni, Angelo
PY - 1991
Y1 - 1991
N2 - Fifty-six patients affected with hereditary angioedema have been followed during long-term prophylaxis with attenuated androgens. The treatment was started in patients who had one or more severe attacks per month. In 24 patients, the therapy lasted for more than 5 years. The minimal effective dose usually did not exceed 2 mg/day of stanozolol or 200 mg/day of danazol. Only in two patients were these doses not sufficient to achieve the complete disappearance of symptoms. Irregular menstruation, but rarely amenorrhea, was the only significant side effect. One patient had to stop the therapy because of laboratory signs of hepatic cell necrosis. In one patient, danazol was administered during the last 8 weeks of pregnancy without side effects for the mother but with transient signs of virilization for the female baby. To find a biochemical marker for the minimal effective dose of androgen derivatives, we measured the plasma levels of C1 C1 INH complexes at different doses of stanozolol in four patients with hereditary angioedema. We found that these complexes, elevated before treatment, promptly reverted to normal values during androgen therapy and remained normal with any reduction of the dose of the drug as long as the patient remained symptom free. Therefore, the measurement of C1 C1 INH complexes appears to reflect the activity of the disease and not the amount of androgen that is administered. (J Allergy Clin Immunol 1991;87:768-73.).
AB - Fifty-six patients affected with hereditary angioedema have been followed during long-term prophylaxis with attenuated androgens. The treatment was started in patients who had one or more severe attacks per month. In 24 patients, the therapy lasted for more than 5 years. The minimal effective dose usually did not exceed 2 mg/day of stanozolol or 200 mg/day of danazol. Only in two patients were these doses not sufficient to achieve the complete disappearance of symptoms. Irregular menstruation, but rarely amenorrhea, was the only significant side effect. One patient had to stop the therapy because of laboratory signs of hepatic cell necrosis. In one patient, danazol was administered during the last 8 weeks of pregnancy without side effects for the mother but with transient signs of virilization for the female baby. To find a biochemical marker for the minimal effective dose of androgen derivatives, we measured the plasma levels of C1 C1 INH complexes at different doses of stanozolol in four patients with hereditary angioedema. We found that these complexes, elevated before treatment, promptly reverted to normal values during androgen therapy and remained normal with any reduction of the dose of the drug as long as the patient remained symptom free. Therefore, the measurement of C1 C1 INH complexes appears to reflect the activity of the disease and not the amount of androgen that is administered. (J Allergy Clin Immunol 1991;87:768-73.).
UR - http://www.scopus.com/inward/record.url?scp=0025874826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025874826&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(91)90120-D
DO - 10.1016/0091-6749(91)90120-D
M3 - Article
C2 - 2013670
AN - SCOPUS:0025874826
VL - 87
SP - 768
EP - 773
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 4
ER -